UVA critical wavelength method inadequate to predict potential UVA absorption -- L'Oreal.
This article was originally published in The Rose Sheet
Executive Summary
UVA CRITICAL WAVELENGTH TEST "NOT ADEQUATE" FOR DETERMINING UVA EFFICACY, L'OREAL maintains in May 15 comments to FDA on the sunscreen tentative final monograph. Following a study evaluation of the proposed in vitro critical wavelength method, L'Oreal found the test "does not provide a quantitative measure of the UVA protection afforded" by a sunscreen. "Since this method does not account for any biological response, it cannot adequately predict a product's protection against UVA effects on the skin," the company states. L'Oreal is working on an alternative testing method to measure UVA protection in sunscreens.
You may also be interested in...
L'Oreal Critical Wavelength Criticism Based On "Flawed" Analysis - P&G
L'Oreal used a "flawed technical analysis" in assessing the critical wavelength method as a UVA sunscreen testing assay, Procter & Gamble asserts in May 2 comments to FDA.
L'Oreal Critical Wavelength Criticism Based On "Flawed" Analysis - P&G
L'Oreal used a "flawed technical analysis" in assessing the critical wavelength method as a UVA sunscreen testing assay, Procter & Gamble asserts in May 2 comments to FDA.
In Vivo UVA Sunscreen Tests "Clinically Irrelevant...Unethical" - Diffey
The use of in vivo methods for UVA sunscreen testing is "clinically irrelevant" and "unethical," Brian Diffey, PhD, Newcastle General Hospital, maintained at the American Association of Dermatology UVA consensus conference in Washington, D.C. Feb. 4.